All In Biotech

Drug Trial Radar · NCT04926701

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects

A First in Human Randomised, Double Blind, Placebo-controlled, Two-part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses (SAD and MAD) of Inhaled ETD001 in Healthy Male and Female Subjects

Last checked: Nov 19, 2026Latest source record: Mar 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

98

Actual

Start

Jun 11, 2021

Primary completion

Mar 22, 2022

Study completion Mar 22, 2022

Sponsor

Lead sponsor
Enterprise Therapeutics LtdIndustry
Sponsor type
Industry
First posted
Jun 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first in human study of ETD001 a new drug being developed for the treatment of cystic fibrosis. The study is a randomised, placebo-controlled, double-blind interventional study to assess the safety, tolerability and pharmacokinetics of single and multiple ascending doses of inhaled ETD001in healthy male and female subjects.

Conditions

  • Cystic Fibrosis

Interventions

  • ETD001 single doseDrug

    Single ascending doses of inhaled ETD001

  • Placebo single doseDrug

    Single doses of inhaled placebo

  • ETD001 multiple twice daily dosesDrug

    Ascending doses of inhaled ETD001 administered twice daily

  • Placebo multiple twice daily dosesDrug

    Doses of inhaled placebo administered twice daily

  • ETD001 multiple once daily dosesDrug

    Doses of inhaled ETD001 administered once daily

  • Placebo multiple once daily dosesDrug

    Doses of inhaled placebo administered once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants reporting one or more treatment emergent adverse event (TEAE)Time frame: Baseline to Week 8
  2. Number of participants who discontinue due to an adverse event (AE)Time frame: Baseline to Week 8
  3. Number of participants who meet the markedly abnormal criteria for 12-lead ECG assessment at least once post doseTime frame: Baseline to Week 8
  4. Number of participants who meet the markedly abnormal criteria for vital signs assessments at least once post doseTime frame: Baseline to Week 8
  5. Number of participants who meet the markedly abnormal criteria for laboratory assessments at least once post doseTime frame: Baseline to Week 8
  6. Number of participants who meet the markedly abnormal criteria for spirometry assessments at least once post doseTime frame: Baseline to Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hammersmith Medicines Research

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.